Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Cash & Equivalents (2016 - 2020)

Monopar Therapeutics (MNPR) has disclosed Cash & Equivalents for 5 consecutive years, with $18.0 million as the latest value for Q3 2020.

  • Quarterly Cash & Equivalents rose 300.1% to $18.0 million in Q3 2020 from the year-ago period, while the trailing twelve-month figure was $18.0 million through Sep 2020, up 300.1% year-over-year, with the annual reading at $13.2 million for FY2019, 91.71% up from the prior year.
  • Cash & Equivalents hit $18.0 million in Q3 2020 for Monopar Therapeutics, up from $12.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $18.0 million in Q3 2020 to a low of $2.9 million in Q4 2016.
  • Historically, Cash & Equivalents has averaged $8.4 million across 5 years, with a median of $7.9 million in 2018.
  • Biggest five-year swings in Cash & Equivalents: tumbled 41.0% in 2019 and later skyrocketed 300.1% in 2020.
  • Year by year, Cash & Equivalents stood at $2.9 million in 2016, then surged by 212.63% to $9.0 million in 2017, then dropped by 23.26% to $6.9 million in 2018, then skyrocketed by 91.71% to $13.2 million in 2019, then surged by 36.09% to $18.0 million in 2020.
  • Business Quant data shows Cash & Equivalents for MNPR at $18.0 million in Q3 2020, $12.5 million in Q2 2020, and $12.6 million in Q1 2020.